NUMC’S EYE CENTER OBTAINS LATEST, MOST ADVANCED MICRO PULSE LASER TECHNOLOGY FOR TREATMENT OF GLAUCOMA, MACULAR DEGENERATION AND DIABETIC RETINAL DISEASE MANAGEMENT

Victor F. Politi, MD, FACP, FACEP                                         Michael B. Mirotznik, Esq.,

President/CEO                                                                             Chairman Board of Directors
FOR IMMEDIATE RELEASE

February 7, 2017

PRESS CONTACT:

Shelley Lotenberg

shelley@numc.edu

516-572-6055

East Meadow, NY………Victor F. Politi, MD, FACP, FACEP, NuHealth/NUMC’s President/CEO announces that the Nassau University Medical Center has obtained the latest and most advanced state-of-the-art MLT IQ532 System (Oculight Visible Green Laser System, 532nm with MicroPulse) for its Eye Center. The laser was purchased through a grant donated by the NuHealth Foundation for $66,750.

“The Eye Center treats thousands of patients with eye diseases each year, with several ophthalmologists specializing in glaucoma and diabetic retinal disease management. At least fifty patients each week, over three thousand a year will have the opportunity to be treated with the most advanced piece of equipment, with a laser providing the safest treatment possible, helping those patients manage glaucoma, complex retinal diseases and macular degeneration,” stated Dr. Politi.

There has been much innovation over the last few years in the treatment of ocular diseases especially in glaucoma and diabetic retinal disease management. One such innovation is MicroPulse Laser Technology.  This is an advanced laser technology that breaks up conventional laser beam into very small, low energy pulses, separated by brief rest period in between.

“This is wonderful state-of-the-art addition to our department. It is a pattern scanning laser delivery device with Automated Fibercheck to ensure fiber optic integrity and Target Cell technology to optimize the physician’s visualization of where laser energy is delivered. Micropulse laser can be used to treat retinal diseases, including diabetic retinopathy, diabetic macular edema (DME) , retinal vein occlusions , central serous retinopathy, and age related macular degeneration, and glaucoma with Micropulse laser trabeculoplasty,” according to Dr. Marcelle Morcos, chair of the department of ophthalmology.

Micropulse laser therapy treatment can be repeated as needed without harm to your vision, and can be combined with drug therapy allowing complete and optimized treatment without conventional laser induced retinal damage. Treatment can be performed in the Eye Center as an Outpatient procedure. Treatment is painless requiring only anesthetic eye drops to perform. The IQ532 system is unique in that it is a single machine capable of delivering both standard photocoagulation and Micropulse technology in the same device. These capabilities enable the use of this unique, single machine for glaucoma, foveal and retinal treatments rather than necessitating the purchase of three separate laser machines.

ABOUT NUHEALTH
NuHealth is a Long Island health care organization delivering essential medical care and disease and lifestyle management to everyone at every stage of life.  Also known as Nassau Health Care Corporation, NuHealth is a public benefit corporation managing the operations of Nassau Medical Center, A. Holly Patterson Extended Care and a network of Family Health Centers that bring primary and specialty care out into the community.  By emphasizing wellness, cultural sensitivity and collaborative efforts with the North Shore-LIJ Health System, NuHealth is working to make good care more affordable and easier to access.

For more information about NuHealth or its Centers of Care, visit www.nuhealth.net.